RTW Biotech Opportunities (LSE:RTW) Total Liabilities: $203.8 Mil (As of Dec. 2025)


LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
36 GF Score
Price $2.47
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Total Liabilities?

RTW Biotech Opportunities LSE:RTW +0.82% 36 Total Liabilities is $203.8 Mil as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

RTW Biotech Opportunities's Total Liabilities for the quarter that ended in Dec. 2025 was $203.8 Mil.

RTW Biotech Opportunities's quarterly Total Liabilities increased from Dec. 2024 ($127.37 Mil) to Jun. 2025 ($180.92 Mil) and increased from Jun. 2025 ($180.92 Mil) to Dec. 2025 ($203.82 Mil).

RTW Biotech Opportunities's annual Total Liabilities increased from Dec. 2023 ($17.21 Mil) to Dec. 2024 ($127.37 Mil) and increased from Dec. 2024 ($127.37 Mil) to Dec. 2025 ($203.82 Mil).

RTW Biotech Opportunities Total Liabilities Related Terms

RTW Biotech Opportunities Total Liabilities Historical Data

* Premium members only.

The historical data trend for RTW Biotech Opportunities's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities Total Liabilities Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial 52.00 53.62 17.21 127.37 203.82

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.21 0.00 127.37 180.92 203.82
LSE:RTW
36GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

RTW Biotech Opportunities's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=1069.042-865.223
=203.8

RTW Biotech Opportunities's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=1069.042-865.223
=203.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $203.8 Mil mean?
RTW Biotech Opportunities (LSE:RTW) has a Total Liabilities of $203.8 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Total Liabilities too high?
RTW Biotech Opportunities' current Total Liabilities is $203.8 Mil. Overall, RTW Biotech Opportunities has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Total Liabilities compare to BLK and BX?
RTW Biotech Opportunities' Total Liabilities of $203.8 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for an Asset Management company?
A good Total Liabilities depends on the Asset Management industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Total Liabilities is $203.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Total Liabilities of $203.8 Mil. The current Total Liabilities is $203.8 Mil. RTW Biotech Opportunities' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Total Liabilities is $203.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
36GF Score

Get the complete analysis for LSE:RTW

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.47
Price